Good demand and high utilisation ratios were behind the record-breaking operating profit in Q2.
Redeye is encouraged to hear that Wyld Networks have signed an agreement with SpaceX to discuss pote...
Storbritannien visar fortsatt styrka mot en svagare nordisk marknad.
Robusta intäkter i andra kvartalet VO2 redovisade intäkter för andra kvartalet som uppgick till 91,7...
Enersense’s Q2 results recovered well from the challenging comparison period, and earnings should ha...
Redeye sees the approval in the Swedish market as the most important in the short perspective as the...
Scanfil’s Q2 results came in somewhat higher than estimated.
Net sales was 3% above consensus (Refinitiv) meanwhile operating profit was 7% above consensus in Q2...
CapMan's Q2 2023 EBIT fell short of Refinitiv consensus expectations, partly explained by fair value...
Ahead of Boreo's Q2 report, we incorporate the Delfin Technologies acquisition into our estimates an...
• EBITDA PLN 60-70m vs. ABGSCe PLN 112m • Miss driven by weaker paper volumes • Destocking likely to...
Enersense’s Q2 figures were better than we estimated as Power and Connectivity revenue clearly toppe...
Redeye comments on yesterday’s ruling in the lawsuit - in which the judge ruled that the whole paten...
Pausar utvecklingen av BupiZenge OncoZenge meddelande under onsdagen att bolaget pausar utvecklingen...
DT posted Q2 net sales in line with our expectations, while adj.
Redeye comments on W5 Solutions Q2-results which were much stronger than expected beating both our g...
CapMan's net sales in Q2 amounted to EUR 16.5m, below our estimates and below consensus (EUR 18.
• H1e: 40.5% y-o-y ARR growth • New major customer win a possibility; cash burn to continue • Liftin...
Redeye updates on Xspray Pharma following its Q2 2023 report.
It is difficult to imagine Aspo posting any positive surprises in the near future.
